Monopar Therapeutics Inc. - MNPR STOCK NEWS

Monopar Therapeutics (Nasdaq: MNPR) has closed its previously announced public offering of common stock, raising $19.2 million in gross proceeds. The shares were priced at $16.25 per share. Notable participants included Janus Henderson Investors and RA Capital Management. Rodman & Renshaw served as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital. The offering was made through a shelf registration statement previously filed with the SEC.

Monopar Therapeutics (Nasdaq: MNPR) has announced the pricing of a public offering of common stock at $16.25 per share, aiming to raise approximately $19.2 million in gross proceeds. The offering, expected to close on October 30, 2024, features participation from notable investors including Janus Henderson Investors and RA Capital Management. Rodman & Renshaw serves as the exclusive placement agent. The company plans to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital.

Monopar Therapeutics (Nasdaq: MNPR) announced plans for a best efforts public offering of common stock. The clinical-stage biotech company intends to use the proceeds for general corporate purposes, including research and development, clinical trials, product manufacturing, and working capital. Rodman & Renshaw is serving as the exclusive placement agent. The offering will be conducted under a previously filed S-3 registration statement. The final terms will be disclosed in a prospectus supplement to be filed with the SEC.

Monopar Therapeutics (Nasdaq: MNPR) has secured an exclusive worldwide license from Alexion, AstraZeneca Rare Disease for ALXN-1840, a Wilson disease drug candidate that completed Phase 3 trials meeting its primary endpoint. The agreement involves an upfront payment combining cash and Monopar equity, plus future tiered royalties and milestone payments. Monopar will oversee all future global development and commercialization. This acquisition follows Alexion's 2023 termination of the ALXN-1840 program after reviewing Phase II mechanistic trials and regulatory discussions.

Monopar Therapeutics Inc. (Nasdaq: MNPR) is presenting encouraging data from its uPAR radiopharmaceutical program at the EANM 2024 Annual Congress. The presentation, recognized as a "Top-Rated Oral Presentation," showcases favorable human clinical dosimetry data for MNPR-101-Lu, derived from MNPR-101-Zr imaging studies.

Key highlights include:

• Favorable organ safety profile at high Lu-177 therapeutic dose levels
• Promising uPAR targeting in solid tumors
• Encouraging tumor uptake and low off-target binding
• Estimated favorable radiation dosimetry safety profile for off-target effects

The company's Phase 1a trial for MNPR-101-Lu (NCT06617169) and Phase 1 imaging and dosimetry trial for MNPR-101-Zr (NCT06337084) are ongoing.

Monopar Therapeutics Inc. (Nasdaq: MNPR) has filed a provisional patent for new therapeutic radiopharmaceuticals based on a family of linkers connecting radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101. The patent filing covers:

• Composition of Matter: Claims for a family of linkers and Monopar's uPAR targeting agents linked with these and therapeutic radioisotopes
• Stability and Biodistribution: Proprietary new linkers designed to enhance stability and biodistribution of Monopar's therapeutic radiopharmaceuticals
• Versatility: The new linker family works with various isotopes and targeting molecules, including small molecules/peptides and antibodies

The company believes these linkers could create new proprietary radiopharmaceuticals targeting high-value cancer targets and potentially lead to licensing and development collaborations in the industry.

Monopar Therapeutics Inc. (Nasdaq: MNPR) has initiated a Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu in patients with advanced cancers. The open-label dose-escalation study will recruit patients with solid tumors, focusing on those participating in the ongoing MNPR-101-Zr Phase 1 imaging and dosimetry trial. The first clinical site activated is the Melbourne Theranostic Innovation Centre (MTIC) in Australia.

MNPR-101 is Monopar's proprietary antibody targeting the urokinase plasminogen activator receptor (uPAR), expressed in various tumor types. The company aims to deliver targeted radiopharma therapy that kills cancer cells while minimizing damage to healthy tissue. Recent clinical and preclinical data have shown highly specific and durable tumor uptake of MNPR-101-Zr.

This trial may be the world's first uPAR-targeted therapeutic radiopharma clinical trial, with the goal of identifying tumors using MNPR-101-Zr and treating them with MNPR-101-Lu.

Monopar Therapeutics Inc. (Nasdaq: MNPR) announced positive early data from its ongoing MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial, validating the tumor targeting ability of MNPR-101-Zr in humans. The trial focuses on MNPR-101, a proprietary first-in-class humanized monoclonal antibody targeting cancers expressing the urokinase plasminogen activator receptor (uPAR).

Key findings include:

• Highly preferential uptake of MNPR-101-Zr in metastatic tumors relative to normal tissue
• Specificity and durability of MNPR-101-Zr in tumor targeting
• Alignment of MNPR-101-Zr uptake with previously observed metastatic tumors on FDG PET imaging

Monopar also received clearance in Australia to initiate an MNPR-101-Lu Phase 1 therapeutic clinical trial, scheduled for Q4 2024. Additional data will be presented at the European Association of Nuclear Medicine 2024 Annual Congress in October.

Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative cancer treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Chandler D. Robinson, MD, Monopar's CEO, will present at the conference. Key details include:

• Presentation will be webcast starting Monday, September 9, 2024 at 7:00 a.m. ET
• In-person one-on-one meetings will be held at the Lotte New York Palace, NY
• Conference dates: September 9 - 11, 2024

This event provides Monopar an opportunity to showcase its progress and connect with potential investors, potentially impacting its stock performance (MNPR).